Hailed as one of Taiwan's leading pharmaceutical and medical science companies as well as the nation's leader in next generation sequencing (NGS), Lihpao Life Science was founded in 2010 with a focus on cancer molecular diagnostics. Affordable Cancer Detection SolutionThe previous generation of detection technology has associated set-up costs of up to NT$80,000. The new method developed by Lihpao and Taipei Veterans General Hospital reduces this figure to approximately NT$25,000. 13, Wu also gave a presentation at forum on the topic of "Precision Medicine in Taiwan." Wu showed the panel how the company had integrated precision medicine into Taiwan's health care.

Source: The China Post May 16, 2017 12:33 UTC